The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 20: 3228 - 3234

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.20.012

Clinical Research

Analysis of factors influencing hyperdynamic circulation indicators in patients with liver cirrhosis and ascites

  • Yanmin ZHENG ,
  • Qingqing WANG ,
  • Shenghao LI ,
  • Ye LI ,
  • Lu. ZHANG
Expand
  • *.School of Public Health，Dali University，Dali 671000，Yunnan，China

Received date: 2025-07-16

  Online published: 2025-11-05

Fold

Abstract

Objective To investigate the factors influencing hyperdynamic circulation-related indicators in patients with liver cirrhosis and ascites. Methods A retrospective analysis was conducted on the clinical data of 377 patients diagnosed with cirrhosis-associated ascites at the Third People's Hospital of Kunming between October 2022 and October 2024. Patients were categorized into grade 1， grade 2， and grade 3 ascites groups according to ascites severity grading. The general demographic characteristics and clinical parameters of the three groups were compared. Potential positive predictors were initially identified through univariate analyses， including Spearman correlation and non-parametric tests. Binary logistic regression and multiple linear regression models were subsequently employed to investigate the factors influencing high dynamic circulation-related indicators （heart rate ［HR］， E/A ratio， and left ventricular diastolic function ［LVDF］） in patients with cirrhosis-related ascites. Results Significant differences in the incidence of HR， the ratio of early to late diastolic filling velocities （E/A）， and LVDF were observed among different ascites groups （P < 0.05）. Age， ascites depth， serum chloride （Cl-）， CO2， red cell distribution width coefficient of variation （RDW-CV）， and etiology were identified as independent determinants of HR in patients with liver cirrhosis and ascites. Age， white blood cell count （WBC）， albumin （ALB）， and etiology were independent determinants of E/A in patients with liver cirrhosis and ascites. Age （OR = 1.088， 95%CI 1.062–1.114， P < 0.001） and serum potassium （K+） （OR = 1.919， 95%CI 1.218–3.025， P = 0.005） were independent risk factors for LVDF in patients with cirrhotic ascites， whereas RDW-CV （OR = 0.902， 95%CI 0.883–0.961， P = 0.023） and ALB （OR = 0.921， 95%CI 0.883–0.961， P < 0.001） were identified as protective factors. Conclusions Serum ALB is an independent influencing factor for E/A ratio and LVDF in cirrhotic patients with ascites and hyperdynamic circulation. K+ and RDW-CV are also independent predictors of LVDF， whereas Cl- independently influences heart rate. Clinical monitoring and targeted intervention for these parameters should be emphasized.

Key words： hyperdynamic circulation; cirrhosis; ascites; influencing factors

Cite this article

Yanmin ZHENG , Qingqing WANG , Shenghao LI , Ye LI , Lu. ZHANG . Analysis of factors influencing hyperdynamic circulation indicators in patients with liver cirrhosis and ascites[J]. The Journal of Practical Medicine, 2025 , 41(20) : 3228 -3234 . DOI: 10.3969/j.issn.1006-5725.2025.20.012

References

[1] XU X， DUAN Z， DING H， et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis［J］. Hepatol Int， 2019， 13（1）： 1-21. doi:10.1007/s12072-018-09923-2
[2] TONON M， PIANO S. Cirrhosis and Portal Hypertension： How Do We Deal with Ascites and Its Consequences［J］. Med Clin North Am， 2023， 107（3）： 505-516. doi:10.1016/j.mcna.2022.12.004
[3] GINéS P， QUINTERO E， ARROYO V， et al. Compensated cirrhosis： natural history and prognostic factors［J］. Hepatology， 1987， 7（1）： 122-128. doi:10.1002/hep.1840070124
[4] 张旭辉， 孟繁坤. 负荷超声心动图在评估肝硬化患者左心功能储备中的应用［J］. 肝脏， 2024， 29（8）： 910-913.
[5] DOURAKIS S P， GELADARI E， GELADARI C， et al. Cirrhotic Cardiomyopathy： The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased？［J］. Curr Cardiol Rev， 2021， 17（1）： 78-84. doi:10.2174/1573403x15666190509084519
[6] 徐小元， 丁惠国， 李文刚， 等. 肝硬化诊治指南［J］. 临床肝胆病杂志， 2019， 35（11）： 2408-2425.
[7] 中华医学会肝病学分会. 肝硬化腹水诊疗指南（2023年版）［J］. 中华肝脏病杂志， 2023， 31（8）： 813-826. doi:10.3760/cma.j.cn501113-20230719-00011
[8] DEBERNARDI VENON W， PUMO S LO， IMPERATRICE B， et al. Transjugular intrahepatic portosystemic shunt in refractory ascites： Clinical impact of left ventricular diastolic dysfunction［J］. Eur J Gastroenterol Hepatol， 2021， 33（1S ）： e464-e470. doi:10.1097/meg.0000000000002151
[9] YOON K T， LIU H， LEE S S. Cirrhotic Cardiomyopathy［J］. Curr Gastroenterol Rep， 2020， 22（9）： 45. doi:10.1007/s11894-020-00783-1
[10] 梁惠颖， 冯凌希， 张舒眉. 超声评估肝硬化患者左室舒张功能及其与BNP相关性分析［J］. 现代医用影像学， 2024， 33（9）： 1703-1706.
[11] SOLANKI R， SREESH S， ATTUMALIL T V， et al. A case-cohort study of left ventricular diastolic dysfunction in patients with cirrhosis： The liver-heart axis［J］. Ann Gastroenterol， 2023， 36（6）： 678-685.
[12] KOK B， ABRALDES J G. Child-Pugh Classification： Time to Abandon？［J］. Semin Liver Dis， 2019， 39（1）： 96-103. doi:10.1055/s-0038-1676805
[13] AKHTAR H， SUDANI H AL， HUSSEIN M， et al. Effects of Renin-Angiotensin-Aldosterone System Inhibition on Left Ventricular Hypertrophy， Diastolic Function， and Functional Status in Patients With Hypertrophic Cardiomyopathy： A Systematic Review［J］. Cureus， 2022， 14（7）： e26642.
[14] PRENNER S B， KUMAR A， ZHAO L， et al. Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction （from the TOPCAT Trial）［J］. Am J Cardiol， 2020， 125（4）： 575-582. doi:10.1016/j.amjcard.2019.11.006
[15] 文蕾， 俞慧宏， 凌贤龙. 肝硬化腹水管理新策略——长期白蛋白治疗［J］. 实用医学杂志， 2024， 40（5）： 591-595.
[16] YU M. Analysis of combined testing results of ALB， CHE， and γ-GT levels in patients with cirrhosis［J］. Minerva Gastroenterol （Torino）， 2024， 70（3）： 395-397. doi:10.23736/s2724-5985.23.03593-3
[17] FERNáNDEZ J， NAVASA M， GARCIA-PAGAN J C， et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis［J］. J Hepatol， 2004， 41（3）： 384-390. doi:10.1016/j.jhep.2004.05.009
[18] 孙蓓蓓， 周强， 张浩. RDW-CV、RDW-SD鉴别诊断肝硬化代偿期与失代偿期的临床应用价值［J］. 安徽医科大学学报， 2021， 56（6）： 938-941.
[19] F?RHéCZ Z， GOMBOS T， BORGULYA G， et al. Red cell distribution width in heart failure： Prediction of clinical events and relationship with markers of ineffective erythropoiesis， inflammation， renal function， and nutritional state［J］. Am Heart J， 2009， 158（4）： 659-666. doi:10.1016/j.ahj.2009.07.024
[20] MORANO I. The Contractile Machines of the Heart［J］. Adv Exp Med Biol， 2024， 1441： 417-433. doi:10.1007/978-3-031-44087-8_21
[21] CHEN Q， MAO R， ZHAO J， et al. Nomograms incorporating preoperative RDW level for the prediction of postoperative complications and survival in colorectal liver metastases after resection［J］. Ann Palliat Med， 2021， 10（4）： 4143-4158. doi:10.21037/apm-20-2418
[22] SANER F H， NEUMANN T， CANBAY A， et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients［J］. Transpl Int， 2011， 24（5）： 425-432. doi:10.1111/j.1432-2277.2011.01219.x
[23] ALUKAL J J， JOHN S， THULUVATH P J. Hyponatremia in Cirrhosis： An Update［J］. Am J Gastroenterol， 2020， 115（11）： 1775-1785. doi:10.14309/ajg.0000000000000786
[24] RADWAN H， IBRAHIM O， BADRA G， et al. Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites［J］. Eur Rev Med Pharmacol Sci， 2022， 26（18）： 6608-6619.
[25] KOSE N， BILGIN F. Successful Treatment of a Patient with Cardiac Arrest Due to Hyperkalemia by Prolonged Cardiopulmonary Resuscitation along with Hemodialysis： A Case Report and Review of the Literature［J］. Medicina （Kaunas）， 2021， 57（8）： 810. doi:10.3390/medicina57080810
[26] KALAMBOKIS G， CHRISTAKI M， TSIAKAS I， et al. Association of left ventricular diastolic dysfunction with inflammatory activity， renal dysfunction， and liver-related mortality in patients with cirrhosis and ascites［J］. Eur J Gastroenterol Hepatol， 2024， 36（6）： 775-783. doi:10.1097/meg.0000000000002762
[27] NAAL T， ABUHALIMEH B， KHIRFAN G， et al. Serum Chloride Levels Track With Survival in Patients With Pulmonary Arterial Hypertension［J］. Chest， 2018， 154（3）： 541-549. doi:10.1016/j.chest.2018.04.022
[28] ZHANG Y， PENG R， LI X， et al. Serum chloride as a novel marker for adding prognostic information of mortality in chronic heart failure［J］. Clin Chim Acta， 2018， 483： 112-118. doi:10.1016/j.cca.2018.04.028
[29] JI Y， LI L. Lower serum chloride concentrations are associated with increased risk of mortality in critically ill cirrhotic patients： An analysis of the MIMIC-III database［J］. BMC Gastroenterol， 2021， 21（1）： 200. doi:10.1186/s12876-021-01797-3
[30] SONI J R， MARRAPU S， KUMAR R. Hypochloremia is an underutilised prognostic marker in patients with advanced liver cirrhosis and liver failure［J］. World J Hepatol， 2025， 17（3）： 103807. doi:10.4254/wjh.v17.i3.103807
[31] XU J， LV Y， ZHAO X， et al. Identification of Sodium- and Chloride-Sensitive Sites in the Slack Channel［J］. J Neurosci， 2023， 43（15）： 2665-2681. doi:10.1523/jneurosci.1365-22.2023
[32] WARNER E R N， ALOOR F Z， SATAPATHY S K. A narrative review of nutritional abnormalities， complications， and optimization in the cirrhotic patient［J］. Transl Gastroenterol Hepatol， 2022， 7： 5. doi:10.21037/tgh-20-325
Options
Outlines

/

〈 〉